• Increase font size
  • Default font size
  • Decrease font size
Message
  • Please Login First
  • Please Login First
  • Please Login First

| Favourites |

What is One Year Subscription?

Author:
BioMedReports.Com
Date added:
Friday, 12 June 2009
Hits:
2262
Rating:
 
Vote for this:
Good  -  Bad
favoured:
0 | Favour

Answer

By signing up for the $250 discounted yearly premium subscription, you can visit all areas of site including the special FDA Decisions Calendar and Clinical Trials Update. By choosing this plan today, you also save 50% over the cost of our monthly subscription plan. This is a limited time only promotion. Prices will be changing for this service soon.

Be aware that due to the nature and value of the information contained in these reports, this is non-refundable 1-year subscription.


The subscriber agrees to these terms and conditions once he clicks and pays below.

Furthermore, these valuable reports are the exclusive property of BiomedReports.Com. Copyright restrictions, absent written authorization prohibit the reproduction, dissemination or use by non-members is unauthorized and strictly prohibited. Digital watermarks and other security features protect this exclusive content so that it may be used by subscribers only

Category

about 10 hours ago FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 1 day ago Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago $CVM up 17% and technically looks like it may head higher.
about 2 days ago $ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr

navigation

Free Phone Trade Alerts